Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: A final report of the Polish Adult Leukemia Group

European Journal of Haematology

Volumn 80, Issue 2, 2008, Pages 115-126

  Wierzbowska, Agnieszka ^a   Robak, Tadeusz ^a   Pluta, Agnieszka ^a   Wawrzyniak, Ewa ^a   Cebula, Barbara ^a   Hołowiecki, Jerzy ^b   Kyrcz Krzemień, Sławomira ^b   Grosicki, Sebastian ^b   Giebel, Sebastian ^b   Skotnicki, Aleksander B ^c   Pia̧tkowska Jakubas, Beata ^c   Kuliczkowski, Kazimierz ^d   Kiełbiński, Marek ^d   Zawilska, Krystyna ^e   Kłoczko, Janusz ^f   Wrzesień Kuś, Agata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cladribine; Purine nucleoside analogs; Refractory acute myeloid leukemia; Relapsed acute myeloid leukemia; Salvage treatment

Indexed keywords

ARABINOSIDE; CLADRIBINE; CYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; BRAIN HEMORRHAGE; BRAIN TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RASH; SEPSIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; MULTIVARIATE ANALYSIS; ODDS RATIO; POLAND; RECURRENCE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 38049153331     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00988.x     Document Type: Article

References (48)

1. Estey E, Dohner H. Acute myeloid leukemia. Lancet 2006 368 : 1894 907.
2. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999 14 : 1051 62.
3. Horowiecki J, Grosicki S, Robak T, et al. Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004 18 : 989 97.
4. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, Harrison G. Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002 118 : 385 400.
5. Cortes J, Estey E, Beran M, O'Brien S, Giles F, Koller C, Keating M, Kantarjian H. Cyclophosphamide, Ara-C, topotecan for patients with refractory or relapsed acute leukemia. Leuk Lymphoma 2000 36 : 479 84.
6. De la Rubia J, Regadera AI, Martin G, et al. FLAG-Ida regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high risk myeloid malignancies. Leuk Res 2002 26 : 725 30.
7. Ferra C, Berlanga J, Gallardo D, Ancin I, Marin D, Gonzales JR, Peris J, Munoz J, Sarra J, Granena A. Mitoxantrone, etoposide, carboplatinum and Ara-C combination therapy (Meca) in refractory and relapsed acute leukemia. Leuk Lymphoma 2000 39 : 583 90.
8. Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wormann B, Buchner T, Hiddemann W for the German AML Cooperative Group. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000 14 : 226 31.
9. Milligan DW, Wheatley K, Littlewood T, et al. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 2006 107 : 4614 22.
10. Robak T, Wrzesień-Kuś A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 2002 43 : 281 91.
11. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988 48 : 329 34.
12. Gandhi V, Plunkett W. Modulatory activity of 2′,2′- difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990 50 : 3675 80.
13. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993 11 : 116 24.
14. Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma 2003 44 : 391 409.
15. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993 9 : 343 50.
16. Tosi P, Visani G, Otaviani E, Manfroi S, Zinzani PL, Tura S. Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994 8 : 2076 82.
17. Braess J, Jahns-Streubel G, Schoch C, Haase D, Haferlach T, Fiegl M, Voss S, Kern W, Schleyer E, Hiddemann W. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. Br J Haematol 2001 113 : 975 82.
18. Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukaemia. Hematologica 1996 81 : 513 20.
19. Nokes TJC, Johnson S, Harvey D, Goldstone AH. FLAG is a useful regimen for poor prognosis adult myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 1997 27 : 93 101.
20. Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998 58 : 105 9.
21. Jackson G, Taylor P, Smith GM, et al. A multicenter, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001 112 : 127 37.
22. Carella MA, Cascavilla M, Greco MM, Lelillo M, Sajeva MR, Ladogana S, D'Arena G, Perla G, Carotenuto M. Treatment of poor risk acute myeloid leukemia with fludarabine, cytarabine and G-CSF (Flag regimen): a single centre study. Leuk Lymphoma 2001 40 : 295 303.
23. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic and molecular interactions. Blood 1996 87 : 256 64.
24. Hubeek I, Peters GJ, Broekhuizen AJ, Sargent J, Gibson BE, Creutzig U, Caspers GJ. Potentiation of in vitro ara-C cutotoxicity by ribonucleoyide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidocolin in pediatric acute myeloid leukemia. Br J Haematol 2005 131 : 219 22.
25. Chow KU, Boehrer S, Napieralski S, Nowak D, Knau A, Hoelzer D, Mitrou PS, Weidmann E. In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma 2003 44 : 165 73.
26. Juliusson G, Hoglund M, Karlsson K, Lofgren C, Mollgard L, Paul C, Tidefelt U, Bjorkholm M. Leukemia Group of Middle Sweden. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 2003 123 : 810 18.
27. Robak T, Wrzesień-Kuś A, Lech-Marańda E, Kowal M, Dmoszyńska A. Combination regimen of cladribine, cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 2000 39 : 121 9.
28. Wrzesień-Kuś A, Robak T, Lech-Marańda E, et al. A multicenter, open, non-comparative phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol 2003 71 : 155 62.
29. Wrzesień-Kuś A, Robak T, Wierzbowska A, et al. A multi center, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadeno-sine), cytarabine, G-CSF and mitoksantron (CLAG-M) as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). Ann Hematol. 2005 84 : 557 64.
30. Cheson BD, Bennett JM, Kopecky KJ, et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia: "revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia". J Clin Oncol 2003 21 : 4642 9.
31. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981 47 : 207 14.
32. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000 96 : 4075 83.
33. Ghandi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002 41 : 93 103.
34. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 1996 10 : 1563 9.
35. Beutler E. Cladribine (2-chlorodeoxuadenosine). Lancet 1992 340 : 952 6.
36. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA, Leoni LM. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000 96 : 3537 43.
37. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005 23 : 1969 78.
38. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004 89 : 998 1008.
39. Weltermann A, Fonatsch C, Haas OA, et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2004 18 : 293 302.
40. Estey E. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000 14 : 476 9.
41. Vidarsson B, Abonour R, Williams EC, Woodson RD, Turman NJ, Kim K, Mosher DF, Wiersma SR, Longo WL. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma 2001 41 : 321 31.
42. Ferrara F, Melillo L, Montillo M, Leoni F, Pinto A, Mele G, Mitro S. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 1999 78 : 380 84.
43. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) in the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997 99 : 939 44.
44. Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, Franklin J, Tesch H, Diehl V, Dias Wickramanayake P. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 1999 78 : 418 25.
45. Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol 2003 82 : 231 5.
46. Hanel M, Friedrichsen K, Hanel A, Herbst R, Morgner A, Neser S, Nicklisch M, Teich M, Ehninger G, Fiedler F. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie 2001 24 : 356 60.
47. Huhmann IM, Watzke HH, Geissler K, et al. FLAG (fluadarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 1996 73 : 265 71.
48. Feldman E, Ghandi V, Plunkett W, et al. Seqenitial administration of fludarabine, ara-C and mitoxantrone enhances topoisimerase II-DNA complex formation and has efficacy in acute leukemia. Blood 1992 80 (Suppl. 1 208a.